|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We found that NRF3 promotes tumor growth and malignancy by activating ubiquitin-independent 20S proteasome assembly through inducing the expression of the proteasome maturation protein (POMP) chaperone and thereby degrading the tumor suppressors p53 and Rb.
|
31742837 |
2020 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Remarkable upregulation of the NRF2 (NFE2L2)-related transcription factor NRF3 (NFE2L3) in several cancer tissues and its correlation with poor prognosis strongly suggest the physiological function of NRF3 in tumors.
|
31288376 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our study showed that shRNA-mediated knockdown of NFE2L3 exhibited tumor-suppressing effects in HCC cells.
|
30886504 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our data demonstrate the first in vivo function of Nrf3 and its link to tumor development.
|
21148084 |
2011 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In this review, we describe recent research advances regarding the new cancer effector NRF3, including unclarified ubiquitin-independent proteolysis by the NRF3-POMP-20S proteasome axis.
|
31742837 |
2020 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, human cancer genome databases suggest critical roles of NRF3 in cancer because of high NRF3 mRNA induction in several cancer types, such as colorectal cancer and pancreatic adenocarcinoma, with a poor prognosis.
|
31742837 |
2020 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In this review, we describe recent research advances regarding the new cancer effector NRF3, including unclarified ubiquitin-independent proteolysis by the NRF3-POMP-20S proteasome axis.
|
31742837 |
2020 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Indeed, we had recently uncovered the function of NRF3, which promotes cancer cell proliferation by p53 degradation via the 20S proteasome.
|
31288376 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
NRF3 loss-increased CRC growth through EGFR and p38 was confirmed in nude mice.
|
30949407 |
2019 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811.
|
31191746 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Indeed, we had recently uncovered the function of NRF3, which promotes cancer cell proliferation by p53 degradation via the 20S proteasome.
|
31288376 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
However, molecular mechanisms underlying the nuclear translocation of NRF3 and its target gene in cancer cells remain poorly understood.
|
28970512 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
However, molecular mechanisms underlying the nuclear translocation of NRF3 and its target gene in cancer cells remain poorly understood.
|
28970512 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Nevertheless, human cancer genome databases suggest critical roles of NRF3 in cancer because of high NRF3 mRNA induction in several cancer types, such as colorectal cancer and pancreatic adenocarcinoma, with a poor prognosis.
|
31742837 |
2020 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> Our findings suggested that NRF3 inhibited breast cancer cell proliferation and metastasis via inhibiting AKT/ID3 axis at least partially, and potentially to be a valuable clinic marker in breast cancer prognosis.
|
31114245 |
2019 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Herein, we found that NRF3 is lowly expressed in colorectal cancer (CRC) tissues and cells, and NRF3 low-expressions in CRC tissue samples are associated with CRC carcinogenesis and poor patient outcomes.
|
30949407 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811.
|
31191746 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, we provide the first evidence to our knowledge that RCAN1-4 is a growth and metastasis suppressor in vivo and that it functions in part through NFE2L3.
|
28289712 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
To examine whether Nrf3 is involved in chemical-induced carcinogenesis, we exposed the mice to benzo[a]pyrene (B[a]P), a carcinogen found in cigarette smoke.
|
21148084 |
2011 |
|
Addictive Behavior
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our group has recently discovered a new addiction to the NRF2-related factor NRF3 (NFE2L3) in cancer.
|
31742837 |
2020 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> NRF3 expression in breast cancer cell lines and clinical specimens was determined by western blot and immunohistochemistry, respectively.
|
31114245 |
2019 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
NFE2L3 Controls Colon Cancer Cell Growth through Regulation of DUX4, a CDK1 Inhibitor.
|
31693889 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
LAT, HOXD3 and NFE2L3 identified as novel DNA methylation-driven genes and prognostic markers in human clear cell renal cell carcinoma by integrative bioinformatics approaches.
|
31777602 |
2019 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found that NFE2L3 expression is regulated by the RELA subunit of NF-κB and that NFE2L3 levels are elevated in patients with colon adenocarcinoma when compared with normal adjacent tissue.
|
31693889 |
2019 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<b>Methods:</b> NRF3 expression in breast cancer cell lines and clinical specimens was determined by western blot and immunohistochemistry, respectively.
|
31114245 |
2019 |